9 patents currently held
106 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2030. from the record
Of the 106 now held by other companies, 72 name Biogen Ma Inc. as their current owner, and 34 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Feb 2030
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2034 · High confidence
Also notable
Ends Aug 2030 · High confidence
Also notable
Ends Jan 2036 · High confidence
Chimeric Factor VIII Polypeptides and Uses Thereof
US 11,370,827
The most cited patent in this portfolio, cited by 43 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Bicyclic Aryl Sphingosine 1-Phosphate Analogs
US 9,572,824
Cited by 17 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Population Pharmacokinetics Tools and Uses Thereof
US 10,325,687
Cited by 22 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2036.
Formerly held, still cited
Notable
Ends Feb 2028 · High confidence
The most cited patent in this portfolio, cited by 108 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2028.
now held by Biogen Ma Inc.
Also notable
Ends Jan 2032 · High confidence
Cited by 101 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
now held by Biogen Ma Inc.
Also notable
Ends no later than Mar 2027 · Medium confidence
Cited by 77 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Biogen Ma Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 4 to 18, 2026 · next Dec 4
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 4 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Population Pharmacokinetics Tools and Uses Thereof | 1 in force | to Jan 2036 |
| Methods and Compositions for Inactivating Enveloped Viruses | 1 in force | to Dec 2034 |
| Factor VIII Polypeptide Formulations | 1 in force | to Nov 2034 |
| Chimeric Factor VIII Polypeptides and Uses Thereof | 1 in force | to Jan 2034 |
| JCV Neutralizing Antibodies | 1 in force | to Mar 2033 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,696,307 | Methods for the Detection of JC Polyoma Virus held by Biogen Ma Inc. In force · Medium confidence | In force | Medium confidence | |
| US 9,572,824 | Bicyclic Aryl Sphingosine 1-Phosphate Analogs In force · High confidence | In force | High confidence | |
| US 10,308,706 | Methods of Preventing and Removing Trisulfide Bonds held by Biogen Ma Inc. In force · High confidence | In force | High confidence | |
| US 9,567,391 | JCV Neutralizing Antibodies held by Biogen Ma Inc. In force · High confidence | In force | High confidence | |
| US 9,567,392 | JCV Neutralizing Antibodies held by Biogen Ma Inc. In force · High confidence | In force | High confidence | |
| US 11,370,827 | Chimeric Factor VIII Polypeptides and Uses Thereof held by Bioverativ Therapeutics Inc. In force · High confidence | In force | High confidence | |
| US 9,623,088 | Factor VIII Polypeptide Formulations held by Bioverativ Therapeutics Inc. In force · High confidence | In force | High confidence | |
| US 10,188,732 | Methods and Compositions for Inactivating Enveloped Viruses held by Biogen Ma Inc. In force · High confidence | In force | High confidence | |
| US 10,325,687 | Population Pharmacokinetics Tools and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 106 patents in force now held by others · 227 patents ended · 334 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.